Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

In March 2026, Novo Nordisk's semaglutide (sold globally as Wegovy and Ozempic) goes off patent. That means a rush of Indian ...

The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections — was cited for having cat hair, pests, and bacteria, a recent FDA inspection showed.